Hong Kong Stock Exchange filings reveal that on July 30, China Universal Asset Management Co., Ltd. increased its position in KEYMED BIO-B (02162) by 203,500 shares.
The transaction was executed at an average price of HK$72.8753 per share, totaling approximately HK$14.83 million.
Following this acquisition, the fund manager's total holdings in the company rose to 15.096 million shares, representing a 5.05% stake in the biotech firm.